睿知中国疾病研究地图
候选清单0

正在招募骨肉瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

ClinicalTrials.gov 上登记的一项骨肉瘤开放试验。牵头方不是本站收录的医院;本站收录的 11 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 11

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中国人民解放军总医院Chinese PLA General Hospital北京医院页面
  2. 研究中心中山大学附属第一医院First Affiliated Hospital of Sun Yat-sen University广州医院页面
  3. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  4. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  5. 研究中心北京大学人民医院Peking University People's Hospital北京医院页面
  6. 研究中心浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面
  7. 研究中心上海市第一人民医院Shanghai General Hospital上海医院页面
  8. 研究中心上海市第六人民医院Shanghai Sixth People's Hospital上海医院页面
  9. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
  10. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
  11. 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05830123,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Patients with histologically confirmed relapsed or refractory osteosarcoma or other sarcomas who have progressed upon first-line systemic treatment.

    入选标准第 2 条

  3. Previous or current treatment with B7-H3 targeted therapy

    排除标准第 2 条

    Prior treatment with a monoclonal antibody within 28 days prior to the first scheduled dose of HS-20093

    排除标准第 4 条

    Radiotherapy with a limited field of radiation for palliation within 2 weeks, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093

    排除标准第 5 条

    Any unresolved toxicities from prior therapy greater than Grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0 with the exception of alopecia or neurotoxicity.

    排除标准第 11 条

    Patients who have received continuous steroid treatment for more than 30 days within 30 days before the first dose, or need long-term (≥ 30 days) steroid treatment, or who have other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation

    排除标准第 21 条

  4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1

    入选标准第 5 条

  5. Diabetes ketoacidosis or hyperglycemia hypertonic occurring within 6 months before the first dose of the study drug, or the glycosylated hemoglobin value ≥ 7.5% in the screening period.

    排除标准第 16 条

  6. At least one measurable lesion according to RECIST 1.1.

    入选标准第 3 条

  7. The presence of active infectious diseases has been known before the first dose such as hepatitis B, hepatitis C, tuberculosis, syphilis, or human immunodeficiency virus HIV infection, etc.

    排除标准第 22 条

  8. Females subjects must not be pregnant at screening or have evidence of non-childbearing potential

    入选标准第 8 条

    Women who are breastfeeding or pregnant or planned to be pregnant during the study period.

    排除标准第 26 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05830123,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. At least age of 18 years at screening;
  2. Patients with histologically confirmed relapsed or refractory osteosarcoma or other sarcomas who have progressed upon first-line systemic treatment.
  3. At least one measurable lesion according to RECIST 1.1.
  4. Agree to provide fresh or archival tumor tissue and peripheral blood samples.
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1
  6. Life expectancy >= 12 weeks
  7. Men or women should be using adequate contraceptive measures throughout the study;
  8. Females subjects must not be pregnant at screening or have evidence of non-childbearing potential
  9. Signed and dated Informed Consent Form

排除标准:Exclusion Criteria:

  1. Treatment with any of the following:
  2. Previous or current treatment with B7-H3 targeted therapy
  3. Any cytotoxic chemotherapy, investigational agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093
  4. Prior treatment with a monoclonal antibody within 28 days prior to the first scheduled dose of HS-20093
  5. Radiotherapy with a limited field of radiation for palliation within 2 weeks, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093
  6. Pleural or peritoneal effusion requiring clinical intervention. Pericardial effusion.
  7. Major surgery within 4 weeks of the first dose of HS-20093.
  8. Spinal cord compression or brain metastases.
  9. Treatment with drugs that are predominantly CYP3A4 strong inhibitors or inducers or sensitive substrates of CYP3A4 with a narrow therapeutic range within 7 days of the first dose of study drug; or requiring treatment with these drugs during the study.
  10. Currently receiving drugs known to prolong QT interval or may cause torsade de pointe; or requiring treatment with these drugs during the study.
  11. Any unresolved toxicities from prior therapy greater than Grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0 with the exception of alopecia or neurotoxicity.
  12. History of other primary malignancies.
  13. Inadequate bone marrow reserve or organ dysfunction
  14. Evidence of cardiovascular risk.
  15. Severe, uncontrolled or active cardiovascular diseases.
  16. Diabetes ketoacidosis or hyperglycemia hypertonic occurring within 6 months before the first dose of the study drug, or the glycosylated hemoglobin value ≥ 7.5% in the screening period.
  17. Severe or poorly controlled hypertension.
  18. Bleeding symptoms with apparent clinical significance or obvious bleeding tendency within 1 months prior to the first dose of HS-20093
  19. Serious arteriovenous thrombosis events occurred within 3 months before the first dose.
  20. Severe infections occurred within 4 weeks before the first dose.
  21. Patients who have received continuous steroid treatment for more than 30 days within 30 days before the first dose, or need long-term (≥ 30 days) steroid treatment, or who have other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation
  22. The presence of active infectious diseases has been known before the first dose such as hepatitis B, hepatitis C, tuberculosis, syphilis, or human immunodeficiency virus HIV infection, etc.
  23. Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Grade B or more severe cirrhosis.
  24. Other moderate or severe lung diseases that may interfere with the detection or treatment of drug-related pulmonary toxicity or may seriously affect respiratory function.
  25. Previous history of serious neurological or mental disorders, including epilepsy, dementia or severe depression and any other status that may interfere in assessment.
  26. Women who are breastfeeding or pregnant or planned to be pregnant during the study period.
  27. Vaccination or hypersensitivity of any level within 4 weeks prior to the first dose of HS-20093
  28. History of severe hypersensitivity reaction, severe infusion reaction or allergy to recombinant human or mouse derived proteins.
  29. Hypersensitivity to any ingredient of HS-20093.
  30. Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator
  31. Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments

引自 ClinicalTrials.gov, NCT05830123, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05830123,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05830123